BR112017019792A2 - formulação oftálmica tópica e uso da mesma. - Google Patents

formulação oftálmica tópica e uso da mesma.

Info

Publication number
BR112017019792A2
BR112017019792A2 BR112017019792A BR112017019792A BR112017019792A2 BR 112017019792 A2 BR112017019792 A2 BR 112017019792A2 BR 112017019792 A BR112017019792 A BR 112017019792A BR 112017019792 A BR112017019792 A BR 112017019792A BR 112017019792 A2 BR112017019792 A2 BR 112017019792A2
Authority
BR
Brazil
Prior art keywords
ophthalmic formulation
topical ophthalmic
bosentan
tardentran
sitaxentan
Prior art date
Application number
BR112017019792A
Other languages
English (en)
Inventor
HERNÁNDEZ PASCUAL Cristina
Bruno Montoro Ronsano José
María Suñé Negre José
Ramón Ticó Grau José
Guerrero Martínez Marta
SIMÓ CANONGE Rafael
Duran Muiños Vicente
Original Assignee
Retinset S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retinset S L filed Critical Retinset S L
Publication of BR112017019792A2 publication Critical patent/BR112017019792A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

a invenção se refere a uma formulação oftálmica tópica que compreende ao menos um antagonista do receptor da endotelina, preferivelmente selecionado de sitaxentano, ambrisentano, atrasentrano, bosentano, macitentano e tezosentano, ou suas misturas, mais preferivelmente bosentano, como ingrediente ativo para prevenir e/ou tratar a neurodegeneração da retina induzida pela diabetes e/ou o envelhecimento.
BR112017019792A 2015-03-27 2016-03-22 formulação oftálmica tópica e uso da mesma. BR112017019792A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201530409A ES2584534B1 (es) 2015-03-27 2015-03-27 Formulación tópica oftálmica de bosentan
PCT/ES2016/070197 WO2016156639A1 (es) 2015-03-27 2016-03-22 Formulación tópica oftálmica de antagonistas del receptor de la endotelina

Publications (1)

Publication Number Publication Date
BR112017019792A2 true BR112017019792A2 (pt) 2018-05-22

Family

ID=55910981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019792A BR112017019792A2 (pt) 2015-03-27 2016-03-22 formulação oftálmica tópica e uso da mesma.

Country Status (9)

Country Link
US (1) US10716750B2 (pt)
EP (1) EP3275429A1 (pt)
JP (1) JP6768780B2 (pt)
KR (1) KR102578102B1 (pt)
CN (2) CN107454841A (pt)
BR (1) BR112017019792A2 (pt)
ES (1) ES2584534B1 (pt)
MX (1) MX2017012428A (pt)
WO (1) WO2016156639A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106924190A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 一种马西替坦微球及其制备方法
KR20200118898A (ko) * 2018-03-07 2020-10-16 팀버 파마슈티칼스, 인코포레이티드 피부 섬유증을 치료하기 위한 조성물 및 방법
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
EP4094759A1 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
IL307997A (en) * 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical preparations and intravitreal drug delivery systems for the treatment of eye diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
US20030176356A1 (en) * 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
JP4725699B2 (ja) * 2002-04-08 2011-07-13 ライオン株式会社 眼科用組成物及び眼科用組成物配合用防腐剤
HUE055815T2 (hu) * 2007-10-05 2021-12-28 Univ Wayne State Vegyületek nyújtott felszabadítására alkalmas dendrimerek
EP2564853B1 (en) * 2007-12-04 2019-02-27 Santen SAS Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
LT2493474T (lt) * 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
RU2015143521A (ru) * 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
BR112016027379A2 (pt) * 2014-05-23 2018-06-26 Ocular Tech Sarl formulações tópicas e seus usos

Also Published As

Publication number Publication date
JP2018512452A (ja) 2018-05-17
US10716750B2 (en) 2020-07-21
MX2017012428A (es) 2018-06-19
CN117582396A (zh) 2024-02-23
KR102578102B1 (ko) 2023-09-13
KR20170130443A (ko) 2017-11-28
EP3275429A1 (en) 2018-01-31
CN107454841A (zh) 2017-12-08
ES2584534B1 (es) 2017-03-13
ES2584534A1 (es) 2016-09-28
WO2016156639A1 (es) 2016-10-06
JP6768780B2 (ja) 2020-10-14
US20180110728A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
BR112017019792A2 (pt) formulação oftálmica tópica e uso da mesma.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2019001292A1 (es) Nuevos derivados de quinolina.
EP3407973A4 (en) BIOLOGICALLY ACTIVE CANNABIDIOL ANALOGS
BR112018007572A2 (pt) composições fungicidas
BR112017026650A2 (pt) composições de metilobacterium antifúngicas e métodos de utilização
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
EP3165227A4 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
CL2016002809A1 (es) Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
CL2015001538A1 (es) Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
EP3636245A4 (en) PRODUCTION OF A WATER-IN-OIL EMULSION COSMETIC
CL2015003286A1 (es) (ciano-dimetil-metil)-(isoxazoles y -[1, 3, 4] tiadiazoles novedosos
EP3180993A4 (en) Composition for improving skin, containing pomegranate concentrate as active ingredient
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
EP3385254A4 (en) 1,2,3-TRIAZOLE DERIVATIVE AND INSECTICIDE / ACARICIDE COMPRISING THE DERIVATIVE AS AN ACTIVE SUBSTANCE
EP3590491A4 (en) COSMETIC COMPOSITION OF OIL-IN-WATER EMULSION
BR112016017557A2 (pt) Métodos para controlar plantas daninhas usando formulações contendo herbicidas flutiacet-metila e hppd, e, composição
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements